Beam Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Okay. So welcome, everybody. My name is John Evans. I'm very excited to be here to tell you a little bit about Beam Therapeutics and our effort to create new precision genetic medicines in the field of base editing. As a reminder, I will be making forward-looking statements today.
So Beam, our vision is to provide lifelong cures for patients suffering from serious diseases. We see real potential for one-time curative therapies, which could be truly disruptive in medicine. We believe gene editing is going to be a treatment for both rare, but ultimately, also more common diseases. And we believe that because these technologies are programmable, they can be true platforms, not just creating one program, but creating multiple medicines rapidly over time.
So to give you a quick tutorial on gene editing. So the state-of-the-art to date in gene editing have been what we call nuclease, most famously CRISPR. So what these tools have done is solve one very important problem, which is how do you target within the genome precisely. There are 3 billion
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
